Moleculin Biotech (MBRX) Depreciation & Amortization (CF) (2016 - 2026)
Moleculin Biotech (MBRX) posted quarterly Depreciation & Amortization (CF) of $9000.0 for Q4 2025, down 70.97% year-over-year from $31000.0 in Q4 2024, and down 57.14% quarter-over-quarter from $21000.0 in Q3 2025.
Moleculin Biotech (MBRX) Depreciation & Amortization (CF) (2016 - 2026) Analysis & Trends
Moleculin Biotech's Depreciation & Amortization (CF) history runs 10 years deep, the most recent figure standing at $9000.0 for Q4 2025.
- In Q4 2025, Depreciation & Amortization (CF) fell 70.97% year-over-year to $9000.0; the TTM figure through Dec 2025 stood at $90000.0 (down 28.0% YoY), while the FY2025 annual figure was $90000.0, down 28.57% from the prior year.
- Depreciation & Amortization (CF) for Q4 2025 stood at $9000.0, down from $21000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $44000.0 in Q1 2021, with the low at $9000.0 in Q4 2025.
- The 5-year median for Depreciation & Amortization (CF) is $32000.0 (2022), against an average of $31800.0.
- The sharpest annual moves came in 2023 and 2025: Depreciation & Amortization (CF) gained 9.38% in 2023, then sank 70.97% in 2025.
- Moleculin Biotech's Depreciation & Amortization (CF) stood at $34000.0 in 2021, then slipped by 5.88% to $32000.0 in 2022, then increased by 9.38% to $35000.0 in 2023, then fell by 11.43% to $31000.0 in 2024, then tumbled by 70.97% to $9000.0 in 2025.
- Business Quant data shows MBRX's Depreciation & Amortization (CF) at $9000.0 in Q4 2025, $21000.0 in Q3 2025, and $29000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Moleculin Biotech | 3.37 Mn | 3.37 Mn | - | 8,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8,000.00 |
| Jun 30, 2026 | 8,000.00 |
| Dec 31, 2025 | 9,000.00 |
| Dec 31, 2025 | 9,000.00 |
| Sep 30, 2025 | 21,000.00 |
| Sep 30, 2025 | 21,000.00 |
| Jun 30, 2025 | 29,000.00 |
| Jun 30, 2025 | 29,000.00 |
| Mar 31, 2025 | 31,000.00 |
| Mar 31, 2025 | 31,000.00 |
| Dec 31, 2024 | 31,000.00 |
| Dec 31, 2024 | 31,000.00 |
| Sep 30, 2024 | 31,000.00 |
| Sep 30, 2024 | 31,000.00 |
| Jun 30, 2024 | 31,000.00 |
| Jun 30, 2024 | 31,000.00 |
| Mar 31, 2024 | 32,000.00 |
| Mar 31, 2024 | 32,000.00 |
| Dec 31, 2023 | 35,000.00 |
| Dec 31, 2023 | 35,000.00 |